Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mitoxantrone hydrochloride liposome
- Development stage
- Phase 3
- Lead developer
- CSPC Zhongqi Pharmaceutical Technology Shijiazhuang
- Modality
- Nucleic Acid-Directed Small Molecules → Small Molecules, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Intravenous
01
Overview
Mitoxantrone hydrochloride liposome is a nano-formulation of the antineoplastic agent mitoxantrone encapsulated in liposomes to enhance tumor targeting and reduce systemic toxicity. It is classified as an anthraquinone (anthracenedione) antibiotic antitumor agent. The drug works primarily by inhibiting topoisomerase II, an enzyme essential for DNA replication and repair, leading to DNA strand breaks and apoptosis in rapidly dividing cancer cells. The liposomal formulation improves pharmacokinetics by prolonging circulation time and increasing accumulation in tumor tissue. Mitoxantrone hydrochloride liposome has been approved in China for relapsed or refractory peripheral T-cell lymphoma (PTCL) and is being investigated for other malignancies including extranodal NK/T cell lymphoma (ENKTL), recurrent/metastatic head and neck cancers, platinum-resistant ovarian cancer, and relapsed/refractory acute myeloid leukemia (AML)[1][2][3][4][5][7].
- Brand names
- PLM60PLM-60PLM 60Lipo-MIT
- Other names
- mitoxantrone liposomemitoxantrone hydrochloride liposomal injection
02
Targets
TOP2A (DNA topoisomerase II)
Beyond the preview
Go deeper on mitoxantrone hydrochloride liposome.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mitoxantrone hydrochloride liposome.